// App-Quantinova.ai

P20 : Low Incidence of Clean Intermittent Catheterization with OnabotulinumtoxinA in Diverse Age Groups of Overactive Bladder Patients and Substantial Improvements in Urinary Symptoms and Quality of Life

Researchers

Presenter

  • Victor Nitti

Principal Investigators

  • Sidney Radomski

  • Eric Rovner

  • Marcus Drake

  • Karel Everaert

  • Christopher Chapple

  • David Ginsberg

  • Tamer Aboushwareb

  • Cheng-Tao Chang

  • Roger Dmochowski

  • Benjamin Brucker

Medical Centers

  • New York University Medical Center, New York City, NY

  • University of Toronto, Toronto, ON, Canada

  • Medcl Univ of South Carolina, Charleston, SC

  • Bristol Urological Institute, Bristol, UK

  • Ghent University Hospital, Ghent, Belgium

  • The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, United Kingdom

  • USC Institute of Urology, Los Angeles, CA

  • Allergan plc, Irvine, CA, USA,

  • Allergan plc, Bridgewater, NJ

  • Vanderbilt University Medical Center, Nashville, TN

Locations

  • United States

  • Canada

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Urology

Disease

  • Bladder dysfunction

  • Overactive Bladder

Biomarkers

  • N/A

Drug/Treatment

  • OnabotulinumtoxinA

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved